The 1st year of the COVID-19 epidemic in Estonia: an interrupted time series of population based nationwide cross-sectional studies.
Uuskula, A.; Kalda, R.; Solvak, M.; Jurisson, M.; Kaarik, M.; Fischer, K.; Keis, A.; Raudvere, U.; vilo, J.; Peterson, H.; Kaarik, E.; Metspalu, M.; Jurgenson, T.; Milani, L.; Kolberg, L.; Tiit, E.-M.; Vassil, K.
Show abstract
BackgroundDecisions about the continued need for control measures and the effect of introducing COVID-19 vaccinations rely on accurate and population-based data on SARS-CoV-2 positivity and risk factors for testing positive. MethodsIn this interrupted time series of population-based nationwide cross-sectional studies, data from nasopharyngeal testing and questionnaires were used to estimate the SARS-CoV-2 RNA prevalence and factors associated with test positivity over the 1st year of the COVID-19 epidemic. The study is registered with the ISRCTN Registry, ISRCTN10182320. ResultsBetween April 23, 2020 and February 2, 2021, results were available from 34,915 individuals and 27,870 samples from 11 consecutive studies. The percentage of people testing positive for SARS-CoV-2 decreased from 0.27% (95% CI 0.10% - 0.59%) in April to 0.04% (95% CI 0.00% - 0.22%) by the end of May and remained very low (0.01%, 95% CI 0.00% - 0.17%) until the end of August, followed by an increase since November (0.37%, 95% CI 0.18% - 0.68%) that escalated to 2.69% (95% CI 2.08% - 2.69%) in January 2021. In addition to substantial change in time, an increasing number of household members (for one additional OR 1.15, 95% CI 1.02-1.29), reporting current symptoms of COVID-19 (OR 2.21, 95% CI 1.59-3.09), and completing questionnaire in the Russian language (OR 1.85, 95% CI 1.15-2.99) were associated with increased odds for SARS-CoV-2 RNA positivity. ConclusionsSARS-CoV-2 population prevalence needs to be carefully monitored as vaccine programmes are rolled out in order to inform containment decisions. Strengths and limitations of this studyO_LIOur study relies upon nation-wide and population-based data on SARS-CoV-2 prevalence, and presents changes in prevalence over the whole 1st year of the Covid-19 epidemic. C_LIO_LIOur analysis of SARS-CoV-2 infection risk factors is not limited to notification or health care-based case data. C_LIO_LISelection bias may have been introduced as a result of low response rate. The direction of bias is unclear, but most likely operates rather uniformly over the period of observation, though this presents less of a threat to the SARS-CoV-2 prevalence trend analysis. C_LIO_LIOur data could be used to adequately project the future course of the SARS-CoV-2 epidemic and the effect of control measures. C_LI
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Serological Survey in a university community after the fourth wave of COVID-19 in Senegal 96%
- COVID-19 pandemic in Saint Petersburg, Russia: combining surveillance and population-based serological study data in May, 2020–April, 2021 96%
- Breakpoint modelling of temporal associations between non-pharmaceutical interventions and the incidence of symptomatic COVID-19 in the Republic of Ireland 95%
Similar papers in this journal
- SARS-CoV-2 seroprevalence and living conditions in Bamako (Mali): a cross-sectional multistage household survey after the first epidemic wave, 2020 95%
- Epidemiology of COVID-19 and effect of public health interventions, Chennai, India, March - October 2020 95%
- Antibody response in individuals affected with Sars-Cov-2 infection: temporal trends and qualitative and quantitative differences in symptomatic and asymptomatic subjects. A Cross Sectional Analysis. Ab-Covid Study 94%
Similar papers in this journal
- Prevalence of anti-SARS-CoV-2 antibodies in people attending the two main Goma markets in the eastern Democratic Republic of Congo 95%
- Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley 95%
- Excess respiratory, circulatory, neoplasm and other mortality rates during the Covid-19 pandemic in the EU and their implications 95%
Similar papers in this journal
- Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark 95%
- Divergences on expected pneumonia cases during the COVID-19 epidemic in Catalonia: A time-series analysis of primary care electronic health records covering about 6 million people 94%
- Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel 94%
Similar papers in this journal
- SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia 95%
- The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide survey in Karnataka, India 94%
- Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.